ClinicalTrials.gg
Sign In

Muscular Dystrophies, Limb-Girdle clinical trials

The registry lists 47 studies for Muscular Dystrophies, Limb-Girdle across more than 10 countries. 10 are recruiting or about to start. 34 of them are mainly about Muscular Dystrophies, Limb-Girdle (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Muscular Dystrophies, Limb-Girdle studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
17
Active, not recruiting
9
Recruiting
7
Terminated
5
Status unknown
3
Withdrawn
3

Phase

Phase 1
14
Phase 2
9
Phase 3
4

Where

United States
30
Denmark
8
United Kingdom
5
Germany
4
Italy
4
France
4

Who runs them

Sarepta Therapeutics, Inc. (9) · Rigshospitalet, Denmark (4) · Cooperative International Neuromuscular Research Group (4) · Virginia Commonwealth University (3) · Neurogen Brain and Spine Institute (2) · aTyr Pharma, Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · ML Bio Solutions, Inc. (2)

Who develops what

Save this set

Every programme with a company-led study here in the last two years, whatever its size: 2 programmes from 1 company, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GlucocorticoidRecent, limited
Evidence
  • NCT06246513 · Sarepta Therapeutics, Inc. · Phase 3 · live · background · “Glucocorticoid” · registered Jan 2024
InflaRx GmbH33% of its industry studies11 study
Adrenal Cortex HormonesRecent, limited
Evidence
  • NCT06952686 · Sarepta Therapeutics, Inc. · Phase 3 · background · “Corticosteroid” · registered Apr 2025
—11 study

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Muscular Dystrophies, Limb-Girdle studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
ATYR-1940002
Ribitol001
Prednisone001
Coenzyme Q10011
Lisinopril011
Deflazacort011
Stem Cell001

Coming up

1phase 3 study under way
6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 (43%) set no upper age limit and 3 (43%) stop at 75 or younger. 5 (71%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (14%) take healthy volunteers.

Recruiting studies that take each age, of 7
AgeWomenMen
105 (71%)5 (71%)
186 (86%)6 (86%)
306 (86%)6 (86%)
406 (86%)6 (86%)
506 (86%)6 (86%)
655 (71%)5 (71%)
754 (57%)4 (57%)
854 (57%)4 (57%)

Across all 47 studies, recruiting or not: 45% stop at 75 or younger and 40% at 65; 64% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 47 of 47. search them.